Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

US Real-world Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab
Headache
Headache Posters (7:00 AM-5:00 PM)
088
Fremanezumab, a fully-humanized monoclonal antibody (IgG2Δa) that selectively targets the calcitonin gene-related peptide (CGRP), is approved for migraine preventive treatment in adults. Decision makers need data on real-world patients receiving fremanezumab to inform treatment-related decisions.
This real-world, retrospective claims analysis examined demographics, clinical characteristics, and treatment patterns for US patients with chronic or episodic migraine (CM/EM) initiating fremanezumab treatment.
The IBM/MarketScan Early View Commercial and Medicare database, which includes healthcare service and outpatient medication prescription data for US insurance beneficiaries was used to identify adult patients (age ≥18 years) with ≥1 pharmacy claim for fremanezumab between October 1, 2018 and March 31, 2019 (index date defined as date of the earliest claim); ≥1 CM or EM diagnosis; 12 months of data before (baseline) and after (follow-up) index; and known dose classification (quarterly or monthly). Adherence was assessed using medication possession ratio (MPR).

1,225 eligible migraine patients were identified. Most patients were female (85%); mean±SD age was 44.6±11.3 years. 67% of patients had EM. The most common comorbidities (by diagnostic code) were anxiety disorders (25%), back pain (23%), hypertension (21%), neck pain (20%), depression (19%), insomnia (17%), sinusitis (17%), and chronic pain (15%). During the pre-index versus post-index period, 93% versus 88% of patients were using migraine-related prescription acute medications, 69% versus 58% were using triptans, and 30% versus 26% were using opioids (all P<0.05 for pre-index vs post-index). From pre-index to post-index, the mean±SD annual number of claims decreased from 9.8±9.5 to 8.0±8.6 for migraine-related prescription acute medications, from 4.3±5.2 to 3.1±4.3 for triptans, and from 1.5±4.1 to 1.2±3.6 for opioids (all P≤0.0005 for pre-index vs post-index). The mean±SD MPR was 0.85±0.19.

Fremanezumab treatment is associated with statistically significant reductions in acute medication claims and good treatment adherence in the first 12 months of use.
Authors/Disclosures
Michael Seminerio
PRESENTER
Michael Seminerio has received personal compensation for serving as an employee of AbbVie.
Stephen F. Thompson Stephen Thompson has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Joshua *use 125685 Cohen (Teva Pharmaceuticals Industries) Joshua Cohen has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Krishna Tangirala (Teva ;Pharmaceuticals) Krishna Tangirala has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Rinat Ariely Rinat Ariely has received personal compensation for serving as an employee of Teva Pharmaceuticals. Rinat Ariely has received stock or an ownership interest from Teva Pharmaceuticals.
Alexander Rubin (Teva Pharmaceuticals NA) Alexander Rubin has nothing to disclose.
Karen Carr (Teva) Karen Carr has received stock or an ownership interest from Teva Pharmaceuticals. An immediate family member of Karen Carr has received stock or an ownership interest from Genentech.
Dawn C. Buse, PhD (Dawn C. Buse, PhD) Dr. Buse has received personal compensation for serving as an employee of Vector Psychometric Group. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Collegium. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie-Allergan. Dr. Buse has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Buse has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Pain and Headache Reports. The institution of Dr. Buse has received research support from Amgen. The institution of Dr. Buse has received research support from FDA. The institution of Dr. Buse has received research support from National Headache Foundation.